These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 7509370

  • 41. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells.
    Smith MS, Koerber KL, Pagano JS.
    J Infect Dis; 1993 Feb; 167(2):445-8. PubMed ID: 7678429
    [Abstract] [Full Text] [Related]

  • 42. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.
    Larder BA, Coates KE, Kemp SD.
    J Virol; 1991 Oct; 65(10):5232-6. PubMed ID: 1716689
    [Abstract] [Full Text] [Related]

  • 43. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients.
    Wildemann B, Haas J, Ehrhart K, Wagner H, Lynen N, Storch-Hagenlocher B.
    Neurology; 1993 Dec; 43(12):2659-63. PubMed ID: 7504798
    [Abstract] [Full Text] [Related]

  • 44. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.
    Gurusinghe AD, Land SA, Birch C, McGavin C, Hooker DJ, Tachedjian G, Doherty R, Deacon NJ.
    J Med Virol; 1995 Jul; 46(3):238-43. PubMed ID: 7561796
    [Abstract] [Full Text] [Related]

  • 45. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.
    Stürmer M, Staszewski S, Doerr HW, Larder B, Bloor S, Hertogs K.
    Antimicrob Agents Chemother; 2003 Jan; 47(1):54-61. PubMed ID: 12499169
    [Abstract] [Full Text] [Related]

  • 46. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase.
    Remington KM, Zhu YQ, Phillips TR, North TW.
    J Virol; 1994 Feb; 68(2):632-7. PubMed ID: 7507182
    [Abstract] [Full Text] [Related]

  • 47. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.
    Larder BA, Kemp SD, Purifoy DJ.
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4803-7. PubMed ID: 2472634
    [Abstract] [Full Text] [Related]

  • 48. Sequence analysis of proviral HIV RT amplified directly by a semi-quantitative technique from AZT treated patients.
    Stein CA, Levantis P, Oxford JS.
    J Med Virol; 1994 Oct; 44(2):115-21. PubMed ID: 7531752
    [Abstract] [Full Text] [Related]

  • 49. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance.
    Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE.
    J Infect Dis; 1994 Feb; 169(2):411-5. PubMed ID: 7508970
    [Abstract] [Full Text] [Related]

  • 50. Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC.
    Gu Z, Gao Q, Faust EA, Wainberg MA.
    J Gen Virol; 1995 Oct; 76 ( Pt 10)():2601-5. PubMed ID: 7595365
    [Abstract] [Full Text] [Related]

  • 51. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates.
    Boucher CA, van Leeuwen R, Kellam P, Schipper P, Tijnagel J, Lange JM, Larder BA.
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1525-30. PubMed ID: 8103317
    [Abstract] [Full Text] [Related]

  • 52. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.
    Moutouh L, Corbeil J, Richman DD.
    Proc Natl Acad Sci U S A; 1996 Jun 11; 93(12):6106-11. PubMed ID: 8650227
    [Abstract] [Full Text] [Related]

  • 53. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine.
    Kaye S, Loveday C, Tedder RS.
    J Med Virol; 1992 Aug 11; 37(4):241-6. PubMed ID: 1383414
    [Abstract] [Full Text] [Related]

  • 54. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase.
    Brun-Vézinet F, Ingrand D, Deforges L, Gochi K, Ferchal F, Schmitt MP, Jung M, Masquelier B, Aubert J, Buffet-Janvresse C.
    J Virol Methods; 1992 May 11; 37(2):177-88. PubMed ID: 1375948
    [Abstract] [Full Text] [Related]

  • 55. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
    Boucher CA, Lange JM, Miedema FF, Weverling GJ, Koot M, Mulder JW, Goudsmit J, Kellam P, Larder BA, Tersmette M.
    AIDS; 1992 Nov 11; 6(11):1259-64. PubMed ID: 1282015
    [Abstract] [Full Text] [Related]

  • 56. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
    Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J, Larder BA.
    J Infect Dis; 1992 Jan 11; 165(1):105-10. PubMed ID: 1370174
    [Abstract] [Full Text] [Related]

  • 57. Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis.
    Jung M, Agut H, Candotti D, Ingrand D, Katlama C, Huraux JM.
    J Acquir Immune Defic Syndr (1988); 1992 Jan 11; 5(4):359-64. PubMed ID: 1372352
    [Abstract] [Full Text] [Related]

  • 58. Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus.
    Gingeras TR, Prodanovich P, Latimer T, Guatelli JC, Richman DD, Barringer KJ.
    J Infect Dis; 1991 Dec 11; 164(6):1066-74. PubMed ID: 1955709
    [Abstract] [Full Text] [Related]

  • 59. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
    Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR.
    J Infect Dis; 1995 May 11; 171(5):1172-9. PubMed ID: 7538548
    [Abstract] [Full Text] [Related]

  • 60. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors.
    Byrnes VW, Emini EA, Schleif WA, Condra JH, Schneider CL, Long WJ, Wolfgang JA, Graham DJ, Gotlib L, Schlabach AJ.
    Antimicrob Agents Chemother; 1994 Jun 11; 38(6):1404-7. PubMed ID: 7522428
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.